Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Early P 1 (1)
P 1 (2)

Trial Status

Not Yet Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07539610Phase 1Not Yet Recruiting

Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

NCT07196111Early Phase 1Not Yet RecruitingPrimary

BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors

NCT07106749Phase 1Recruiting

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies

Showing all 3 trials

Research Network

Activity Timeline